Potential benefits of eicosapentaenoic acid on atherosclerotic plaques

Fruchart, 2014, Residual macrovascular risk in 2013: what have we learned?, Cardiovasc. Diabetol., 13, 26, 10.1186/1475-2840-13-26 Bentzon, 2014, Mechanisms of plaque formation and rupture, Circ. Res., 114, 1852, 10.1161/CIRCRESAHA.114.302721 Lamon, 2008, Inflammation at the molecular interface of atherogenesis: an anthropological journey, Am. J. Pathol., 173, 1253, 10.2353/ajpath.2008.080442 Borow, 2015, Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis, Atherosclerosis, 242, 357, 10.1016/j.atherosclerosis.2015.07.035 Budoff, 2016, Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease, Am. J. Cardiol., 118, 138, 10.1016/j.amjcard.2016.04.004 Patel, 2016, Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia, Curr. Opin. Endocrinol. Diabetes Obes., 23, 145, 10.1097/MED.0000000000000233 Gdula-Argasinska, 2015, n-3 Fatty acids as resolvents of inflammation in the A549 cells, Pharmacol. Rep., 67, 610, 10.1016/j.pharep.2015.01.001 Serhan, 2014, Pro-resolving lipid mediators are leads for resolution physiology, Nature, 510, 92, 10.1038/nature13479 Amano, 2011, Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study, Atherosclerosis, 218, 110, 10.1016/j.atherosclerosis.2011.05.030 Urabe, 2013, Association between serum levels of n-3 polyunsaturated fatty acids and coronary plaque detected by coronary computed tomography angiography in patients receiving statin therapy, Circ. J., 77, 2578, 10.1253/circj.CJ-13-0257 Lee, 2009, Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction–data from Infarction Prognosis Study (IPS) registry, Circ. J., 73, 2250, 10.1253/circj.CJ-09-0327 Harris, 2013, Red blood cell fatty acid levels improve GRACE score prediction of 2-yr mortality in patients with myocardial infarction, Int. J. Cardiol., 168, 53, 10.1016/j.ijcard.2012.09.076 Cawood, 2010, Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability, Atherosclerosis, 212, 252, 10.1016/j.atherosclerosis.2010.05.022 Mason, 2016, Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents, J. Cardiovasc. Pharmacol., 68, 33, 10.1097/FJC.0000000000000379 Tanaka, 2014, Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia, Atherosclerosis, 237, 577, 10.1016/j.atherosclerosis.2014.10.011 Matsumoto, 2008, Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice, Atherosclerosis, 197, 524, 10.1016/j.atherosclerosis.2007.07.023 Salic, 2016, Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin, Atherosclerosis, 250, 158, 10.1016/j.atherosclerosis.2016.05.001 Nakajima, 2011, Orally administered eicosapentaenoic acid induces rapid regression of atherosclerosis via modulating the phenotype of dendritic cells in LDL receptor-deficient mice, Arterioscler. Thromb. Vasc. Biol., 31, 1963, 10.1161/ATVBAHA.111.229443 Lau, 2011, Eicosapentaenoic acid and regression of atherosclerotic lesions: a role for dendritic cells, Arterioscler. Thromb. Vasc. Biol., 31, 1943, 10.1161/ATVBAHA.111.231910 Burrill, 2007, Multidetector computed tomographic angiography of the cardiovascular system, Postgrad. Med. J., 83, 698, 10.1136/pgmj.2007.061804 Goel, 2015, Imaging modalities to identity inflammation in an atherosclerotic plaque, Radiol. Res. Pract., 2015, 410967 Hoffmann, 2006, Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography, J. Am. Coll. Cardiol., 47, 1655, 10.1016/j.jacc.2006.01.041 Kawasaki, 2002, In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings, Circulation, 105, 2487, 10.1161/01.CIR.0000017200.47342.10 Puri, 2013, Exploring coronary atherosclerosis with intravascular imaging, Int. J. Cardiol., 168, 670, 10.1016/j.ijcard.2013.03.024 Yamaki, 2012, Comparison between integrated backscatter intravascular ultrasound and 64-slice multi-detector row computed tomography for tissue characterization and volumetric assessment of coronary plaques, Cardiovasc. Ultrasound, 10, 33, 10.1186/1476-7120-10-33 Ando, 2015, Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography: a randomized controlled trial [abstract 12007], Circulation, 132, 10.1161/circ.132.suppl_3.12007 Domei, 2013, Eicosapentaenoic acid reduced the progression of the coronary atherosclerosis in the patients with optimal LDL cholesterol lowering therapy [abstract P689], Eur. Heart J., 34, 137 Katoh, 2011, Daily intake of eicosapentaenoic acid inhibits the progression of carotid intimal-media thickness in patients with dyslipidemia [in Japanese], Ther. Res., 32, 863 Maeda, 2014, Ther. Res., 35, 177 Mita, 2007, Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes, Atherosclerosis, 191, 162, 10.1016/j.atherosclerosis.2006.03.005 Nagahara, 2016, The impact of eicosapentaenoic acid on prevention of plaque progression detected by coronary computed tomography angiography [abstract P5235], Eur. Heart J., 37, 1052 Niki, 2016, Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound, Circ. J., 80, 450, 10.1253/circj.CJ-15-0813 Nishio, 2014, Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma, Atherosclerosis, 234, 114, 10.1016/j.atherosclerosis.2014.02.025 Shintani, 2012, The impact of a pure-EPA omega-3 fatty acid on coronary plaque stabilization: a plaque component analysis with 64-slice multi-detector row computed tomography [abstract], J. Am. Coll. Cardiol., 59, 10.1016/S0735-1097(12)61732-X Takaki, 2011, Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study, J. Atheroscler. Thromb., 18, 857, 10.5551/jat.7260 Uehara, 2013, The additional effect of eicosapentanoic acid on coronary plaque stability in stable angina patients with statin use by optical coherence tomography analysis [abstract P5495], Eur. Heart J., 34, 1011 Wakita, 2013, High-purity-eicosapentaenoic-acid in addition to a strong statin makes regression of coronary plaque in patients with angina-pectoris and impaired glucose tolerance [abstract], Circ. J., 77, I-2678 Yamano, 2015, Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study, J. Atheroscler. Thromb., 22, 52, 10.5551/jat.25593 Gorenoi, 2012, CT coronary angiography vs. invasive coronary angiography in CHD, GMS Health Technol. Assess., 8 Koyama, 2010, A case of borderline diabetes mellitus with plaque regression/stabilization on coronary computed tomographic angiography treated with a high-purity EPA agent, Ther. Res., 1 Boogers, 2012, Automated quantification of coronary plaque with computed tomography: comparison with intravascular ultrasound using a dedicated registration algorithm for fusion-based quantification, Eur. Heart J., 33, 1007, 10.1093/eurheartj/ehr465 O'Leary, 2010, Imaging of atherosclerosis: carotid intima-media thickness, Eur. Heart J., 31, 1682, 10.1093/eurheartj/ehq185 Jegere, 2014, Use of intravascular imaging in managing coronary artery disease, World J. Cardiol., 6, 393, 10.4330/wjc.v6.i6.393 Watanabe, 2014, Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-rationale and design, J. Cardiol., 64, 236, 10.1016/j.jjcc.2013.12.008 Burke, 1997, Coronary risk factors and plaque morphology in men with coronary disease who died suddenly, N. Engl. J. Med., 336, 1276, 10.1056/NEJM199705013361802 Stone, 2011, A prospective natural-history study of coronary atherosclerosis, N. Engl. J. Med., 364, 226, 10.1056/NEJMoa1002358 Tian, 2014, Prevalence and characteristics of TCFA and degree of coronary artery stenosis: an OCT, IVUS, and angiographic study, J. Am. Coll. Cardiol., 64, 672, 10.1016/j.jacc.2014.05.052 Norata, 2010, The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases, Trends Cardiovasc. Med., 20, 35, 10.1016/j.tcm.2010.03.005 Rolph, 2002, Production of the long pentraxin PTX3 in advanced atherosclerotic plaques, Arterioscler. Thromb. Vasc. Biol., 22, e10, 10.1161/01.ATV.0000015595.95497.2F Nagahara, 2016, Eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio as an associated factor of high risk plaque on coronary computed tomography in patients without coronary artery disease, Atherosclerosis, 250, 30, 10.1016/j.atherosclerosis.2016.04.026 Itakura, 2011, Relationships between plasma fatty acid composition and coronary artery disease, J. Atheroscler. Thromb., 18, 99, 10.5551/jat.5876 Nozue, 2013, A predictor of atheroma progression in patients achieving very low levels of low-density lipoprotein cholesterol, Am. J. Cardiovasc. Dis., 3, 255 Wakabayashi, 2015, Low eicosapentaenoic acid to arachidonic acid ratio is associated with thin-cap fibroatheroma determined by optical coherence tomography, J. Cardiol., 66, 482, 10.1016/j.jjcc.2015.01.008 Iwamatsu, 2016, Which has the stronger impact on coronary artery disease, eicosapentaenoic acid or docosahexaenoic acid?, Hypertens. Res., 39, 272, 10.1038/hr.2015.143 Domei, 2012, Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention, Circ. J., 76, 423, 10.1253/circj.CJ-11-0941 Nakahara, 2016, Eicosapentaenoic acid added to strong statin therapy, Circ. J., 80, 321, 10.1253/circj.CJ-15-1352 Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 Nosaka, 2017, Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study, Int. J. Cardiol., 228, 173, 10.1016/j.ijcard.2016.11.105 2016 Bays, 2016, Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies, Prostaglandins Other Lipid Mediat., 125, 57, 10.1016/j.prostaglandins.2016.07.007 Bhatt, 2017, Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial, Clin. Cardiol., 10.1002/clc.22692 Ballantyne, 2016, Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies, J. Clin. Lipidol., 10, 635, 10.1016/j.jacl.2016.02.008 Ballantyne, 2012, Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study), Am. J. Cardiol., 110, 984, 10.1016/j.amjcard.2012.05.031 Ballantyne, 2016, Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies, Atherosclerosis, 253, 81, 10.1016/j.atherosclerosis.2016.08.005 Ballantyne, 2015, Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR study), J. Clin. Lipidol., 9, 377, 10.1016/j.jacl.2014.11.009 Bays, 2013, Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies, Am. J. Cardiovasc. Drugs, 13, 37, 10.1007/s40256-012-0002-3 Bays, 2011, Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, plAcebo-controlled, randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial), Am. J. Cardiol., 108, 682, 10.1016/j.amjcard.2011.04.015 Braeckman, 2013, Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study), Prostaglandins Leukot. Essent. Fat. Acids, 89, 195, 10.1016/j.plefa.2013.07.005 Juliano, 2015 Sakakura, 2013, Pathophysiology of atherosclerosis plaque progression, Heart Lung Circ., 22, 399, 10.1016/j.hlc.2013.03.001 Jacobson, 2012, Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review, J. Clin. Lipidol., 6, 5, 10.1016/j.jacl.2011.10.018 Wei, 2011, Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis, Curr. Atheroscler. Rep., 13, 474, 10.1007/s11883-011-0210-3 Dawson, 2012, Modulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men, J. Nutr. Biochem., 23, 616, 10.1016/j.jnutbio.2011.03.004 Ishida, 2013, Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: participation of cholesterol ester transfer protein and LDL receptor, Prostaglandins Leukot. Essent. Fat. Acids, 88, 281, 10.1016/j.plefa.2013.01.001 Mason, 2016, Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes, Biochim. Biophys. Acta, 1858, 3131, 10.1016/j.bbamem.2016.10.002 Davidson, 2007, Efficacy and tolerability of adding prescription omega-3 fatty acids 4g/d to simvastatin 40mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study, Clin. Ther., 29, 1354, 10.1016/j.clinthera.2007.07.018 Kastelein, 2014, Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial, J. Clin. Lipidol., 8, 94, 10.1016/j.jacl.2013.10.003 Maki, 2013, A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial), Clin. Ther., 35, 1400, 10.1016/j.clinthera.2013.07.420